Risk intervention in persons with diabetes mellitus in Norwegian general practice;Risikointervensjon ved diabetes i allmennpraksis

Tidsskrift for den Norske Laegeforening

Volumn 124, Issue 11, 2004, Pages 1508-1510

  Claudi, Tor ^a   Cooper, John G ^b   Hausken, Marie Fjelde ^c   Michaelsen, Tore ^c   Harboe, Knut ^c   Ingskog, Wibeche ^d   Østrem, Anders ^e  

^a Rønvik Legesenter   (Norway)

^b Sentralsjukehuset I Rogaland   (Norway)

^c Sentralsjukehuset i Rogaland ^*

^d AKER UNIVERSITY HOSPITAL   (Norway)

^e Gransdalen Legesenter   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; FIBRINOLYTIC AGENT; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CONTROLLED STUDY; DIABETES CONTROL; DIABETES MELLITUS; DYSLIPIDEMIA; GENERAL PRACTICE; HEALTH CARE QUALITY; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; NORWAY; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; PRIMARY MEDICAL CARE; RISK REDUCTION; SECONDARY PREVENTION; SMOKING HABIT; FEMALE; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE; MALE; MIDDLE AGED; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROFESSIONAL PRACTICE; RISK FACTOR; SMOKING; STANDARD;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; ASPIRIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FAMILY PRACTICE; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; NORWAY; PROFESSIONAL PRACTICE; QUALITY ASSURANCE, HEALTH CARE; RISK FACTORS; SMOKING;

EID: 2942665989     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Midthjell K, Bjørndal A, Holmen J, Krüger Ø, Bjartveit K. Prevalence of known and unknown diabetes mellitus and impaired glucose tolerance in an adult Norwegian population. Indications of an increasing diabetes prevalence. The North-Trøndelag Diabetes Study. Scand J Prim Health Care 1995; 13: 229-35.
2. Zimmet P, Shaw J, Murray S, Sicree R. The diabetes epidemic in full flight: forecasting the future. Spesialnummer. Diabetic Voice 2003; 48: 12-6.
3. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subject with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
4. Evans JMM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ 2002; 324: 1389-93.
5. Report of a WHO consultation. Definition, diagnoses and classification of diabetes mellitus and its complications. Part 1: Diagnoses and classification of diabetes mellitus. Genève: WHO, 1999.
6. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62.
7. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The antihypertensive and lipid-lowering treatment to prevent heart attac trial (ALLHAT). JAMA 2002; 288: 2981-97.
8. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
9. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-12.
10. Gæde P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen P. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93.
11. Claudi T, Cooper J, Skogøy K, Hausken MF, Melbye H. Diabetesomsorg i norsk allmennpraksis. En tilstandsrapport fra Salten og deler av Rogaland. Tidsskr Nor Lægeforen 1997; 117: 3661-4.
12. Carlsen T, Bratland Z, Claudi T, Cooper J, Telje J, Waaler HM et al. Effektiv lasring med data fra egen praksis - erfaringer fra SATS-prosjektet. Tidsskr Nor Lægeforen 1999; 119: 4603-9.
13. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Heart Protection Collaborative Group. Lancet 2003; 361: 2005-16.
14. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE sub-study. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Lancet 2000; 355: 253-9.
15. Terapianbefaling: Behandling av hyperlipidemi. Nyttfra Statens legemiddelkontroll 1995: 7. Oslo: Statens legemiddelkontroll, 1995.
16. Terapianbefaling: Behandling av hyperlipidemi. SLK-publikasjon 2000: 6. Oslo: Statens legemiddelkontroll, 2000.
17. Claudi T, Cooper JG, Midthjell K, Daae C, Furuseth K, Hanssen KF. NSAMs handlingsprogram for diabetes i allmennpraksis. Skriftserie for leger: Utdanning og kvalitetssikring. Oslo: Norsk selskap for allmennmedisin, Den norske lægeforening, Norges Diabetesforbund, Statens institutt for folkehelse, 2000.
18. Birkeland KI, Claudi T, Hansteen V, Hanssen KF, Hjermann I, Jenssen T et al. Forebygging av hjerte- og karsykdom hos pasienter med type 2-diabetes. Tidsskr Nor Lægeforen 2000; 120: 2554-9.
19. Russel MA, Wilson C, Taylor C, Baker CD. Effect of general practition' advice against smoking. BMJ 1979; 2: 231-5.